Search results (128)
« Back to PublicationsSARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study.
Journal article
Brugha R. et al, (2026), J Pediatr, 289
Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.
Journal article
Kelly E. et al, (2026), J Infect, 92
B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.
Journal article
Bundi CK. et al, (2026), Front Immunol, 17
Structural basis for synergistic antibody protection against the essential malaria invasion complex protein RIPR
Preprint
Williams BG. et al, (2025)
Structural basis for synergistic antibody protection against the essential malaria invasion complex protein RIPR
Preprint
Williams BG. et al, (2025)
B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings
Preprint
Bundi CK. et al, (2025)
Diagnosis of Plasmodium falciparum malaria at very low parasitaemias using a commercially available LAMP assay and RDT.
Journal article
Payne RO. et al, (2025), Trans R Soc Trop Med Hyg, 119, 1149 - 1156
Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection.
Journal article
Hou MM. et al, (2025), Nat Commun, 16
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.
Journal article
Janani L. et al, (2025), J Infect, 91
Plasmodium falciparum infection induces T cell tolerance that is associated with decreased disease severity upon re-infection.
Journal article
Muñoz Sandoval D. et al, (2025), J Exp Med, 222
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.
Journal article
Natama HM. et al, (2025), Lancet Infect Dis, 25, 495 - 506
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development.
Journal article
Siegal EZ. et al, (2025), NPJ Vaccines, 10
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Journal article
Venkatraman N. et al, (2025), Lancet Microbe, 6